BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15900581)

  • 1. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
    Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.
    van der Vliet HJ ; Nishi N; Koezuka Y; von Blomberg BM ; van den Eertwegh AJ ; Porcelli SA; Pinedo HM; Scheper RJ; Giaccone G
    J Immunol Methods; 2001 Jan; 247(1-2):61-72. PubMed ID: 11150537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
    Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
    Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.
    Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T
    J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
    Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
    J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
    Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
    Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells.
    Imataki O; Heike Y; Ishida T; Takaue Y; Ikarashi Y; Yoshida M; Wakasugi H; Kakizoe T
    J Immunother; 2006; 29(3):320-7. PubMed ID: 16699375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expansion and cytokine secretion profile of human valpha24(+) NKT cells from different sources].
    Zhai WH; Huang Y; Wang M; Zhou Z; Zhai WJ; Zhang RL; Zhang P; Han MZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):633-6. PubMed ID: 19549378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
    Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
    J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha.
    Della Bella S; Nicola S; Riva A; Biasin M; Clerici M; Villa ML
    J Leukoc Biol; 2004 Jan; 75(1):106-16. PubMed ID: 14525963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.